Explore the latest advancements in bispecific antibodies for multiple myeloma, focusing on early treatment opportunities and innovative trial designs. In this episode, experts discuss the reemergence ...

The hottest cancer technology from the turn of the century is finally getting its glow-up moment, as clinical trials continue to show that antibody-drug conjugates (ADCs) perform better than standard ...